NCT00761436终止2 期
Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.
Bayer1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2000年2月29日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- The primary outcome measure for evaluating efficacy will be the motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) (version 3.0) in the practically defined "off" state. During the Screening and at Baseline Evaluations.
研究概览
简要总结
Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Idiopathic Parkinson's disease (PD). As defined by:
- •presence of bradykinesia and either rest tremor or rigidity
- •history of asymmetry of PD signs
- •history of progression of PD signs, and
- •no other suspected cause of PD signs
- •Patient is between 40 and 70 years of age, inclusive
- •Patient is L-dopa-sensitive and has unequivocal clinical "off" periods as documented by home diary, completed on 4 consecutive days with an average of 1.5 hours/day in the clinically "off" state
- •Patient is Hoehn & Yahr stage III or higher in the practically defined "off" phase
- •All other medical problems are stable or under control and are not contraindications to general anesthesia or stereotactic neurosurgery
- •Patient's brain magnetic imaging resonance (MRI) shows no abnormality that would contraindicate Spheramine implantation
- •Patient does not have a major psychiatric problem or dementia
- •Patient must give written informed consent to participate in this study
- •Patient must be on a stable dose of antiparkinsonian medication for at least 1 month prior to completion of the home diary assessment and the baseline UPDRS assessments
- •If the patient is a woman of childbearing potential, she must not be nursing or pregnant and must use an adequate form of birth control for the duration of the study deemed appropriate by the investigator such as oral contraceptives, IUD, or condoms
- •Patient must be living with or in close constant contact with a person who can contribute information as to the patient's condition before and after implant and provide assistance, if necessary
排除标准
- •Patients with atypical Parkinson's disease (e.g. parkinsonian "plus" syndrome, secondary Parkinsonian syndrome)
- •Patients exhibiting only a tremor-based symptomatology
- •Patients exhibiting very severe dyskinesias (lasting more than 2 hour/day) exacerbated by L-dopa, evaluated as 4/4 on the dyskinesia scale (violent dyskinesias, incompatible with any normal motor task)
- •Women of childbearing potential without contraception
- •Patients who are non-cooperative or incapable of completing self-evaluation scales or diaries
- •Patients presenting with known pharmacologic immunosuppression related to chemotherapeutic treatment for malignancy, autoimmune disease, allografts or other medical conditions associated with immunosuppression
- •Patient's cardiovascular, pulmonary, renal and hematological state contraindicates use of general anesthesia
- •Evidence of abnormal coagulation including PT > 13 sec, PT > 35 sec or platelets < 5 ml
- •Patients having had previous stereotactic brain surgery
- •Patients treated by apomorphine pump
- •Patients with significant cognitive impairment, untreated or treatment resistant depression, psychosis, hallucinations or delusions that would prevent their effective participation in the study
- •Patients who have participated in another experimental drug or device trial in the past 30 days
研究组 & 干预措施
Arm 1
Experimental
干预措施: Spheramine (BAY86-5280) (Biological)
结局指标
主要结局
The primary outcome measure for evaluating efficacy will be the motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) (version 3.0) in the practically defined "off" state. During the Screening and at Baseline Evaluations.
时间窗: Evaluations, and at approximately 1, 3, 6, 9, 12, 15, 18 and 24 months post-implantation and annually thereafter, the patients Parkinson's symptomatology will be evaluated both on their baseline drug therapy and in the practically defined "off" period.
次要结局
- Neuropsychological Evaluations(Will occur pre-operatively and at 3, 12 and 24 months post-operatively)
- Involuntary Movements, time Motor Tests(Performed during defined "off" and best "on" states)
- Motor Fluctuation and Percent OFF Time Evaluation(Daily "on" phases, "off" phases and hours of sleep per day, using Home Diary)
- Quality of Life and Physician's and Patients Global Evaluations(Every visit until year 5)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
Stereotactic Transplantation of hAESCs for Parkinson's DiseaseParkinson's DiseaseNCT04414813Shanghai East Hospital3
Unknown
不适用
Effectiveness and Reliability of Hypnosis in StereotaxyDystonia, PrimaryTremor, EssentialParkinson DiseaseNCT03074422University Hospital, Geneva22
进行中（未招募）
2 期
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain MetastasisMetastatic Malignant Neoplasm in the BrainStage IVA Lung Cancer AJCC v8Metastatic Lung Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8NCT04516070M.D. Anderson Cancer Center55
招募中
2 期
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）Unresectable Locally Recurrent Rectal CancerNCT06767007Sixth Affiliated Hospital, Sun Yat-sen University31
招募中
不适用
Focal Radiotherapy for Previously Treated Prostate Cancer PatientsLocally Recurrent Prostate CancerNCT03073278Royal North Shore Hospital36